Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells

Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases

Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.

Inclusion Criteria:

• patients with primary refractory or relapsed disease (including relapse after previous SCT and active disease)
• AML in complete remission of refractory
• MDS RAEB-t/secondary AML
• ALL
• CML
• Non-Hodgkin Lymphoma / Hodgkin Lymphoma
• non malignant diseases (aplastic anemia, thalassemia, SCID)
• relapsed Neuroblastoma
• relapsed soft tissue sarcoma (Rhabdomyosarcoma, Ewing sarcoma, PNET
• soft tissue sarcoma with primary bone metastases or bone marrow
• in whom no matched donor was available,

Exclusion Criteria:

• < 6 months after previous HSCT
• active cerebral seizure conditions
• massive progression of leukemias or solid tumours before planned trp.
• left ventricular ejection fraction <25%
• creatinine clearance <40ml/min before conditioning
• respiratory insufficiency with oxygen demand or DLCO <30%
• Bilirubin >4mg/dl, GOT/GPT >400
• severe infection (HIV, Aspergillosis)
• pregnancy